FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:446-448 August 8, 2002 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Farrell, R. J. PubMed Citation

To the Editor: In the review of celiac sprue by Farrell and Kelly (Jan. 17 issue),¹ the suggested diagnostic approach and the information in Table 2 (positive and negative predictive values of diagnostic serologic tests) may be misleading. For antiendomysial antibodies, the positive predictive value of 98 to 100 percent is based on studies of populations in which the prevalence of the disease is about 50 percent² — that is, there is a high level of diagnostic suspicion. However, the post-test probability (predictive value) for a patient with a positive test for antiendomysial antibodies depends on the pretest probability. The . . . [Full Text of this Article]

This article has been cited by other articles:

• Deininger, M. W. N., Druker, B. J. (2003). Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib. Pharmacol. Rev. 55: 401-423 [Abstract] [Full Text]  
• Deininger, M. W.N., O'Brien, S. G., Ford, J. M., Druker, B. J. (2003). Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib. JCO 21: 1637-1647 [Abstract] [Full Text]